The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Overview of the Phase I study with acalabrutinib (ACP-196) in CLL
Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 965 of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.
